​

Crescent Biopharma (CBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CBIO Stock Forecast

Crescent Biopharma (CBIO) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $29.00, with a high of $29.00 and a low of $29.00. This represents a 67.44% increase from the last price of $17.32.

CBIO Stock Rating

Crescent Biopharma stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (61.54%), 5 Hold (38.46%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 5 8 Strong Sell Sell Hold Buy Strong Buy

CBIO Price Target Upside V Benchmarks

TypeNameUpside
StockCrescent Biopharma67.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$31.40
Last Closing Price$17.32$17.32$17.32
Upside/Downside--81.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 26161--8
Jul, 26161--8
Jun, 26171--9
May, 2618---9
Apr, 2618---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Stephen WilleyStifel Nicolaus$29.00$12.35134.82%67.44%
Jan 28, 2026Piper Sandler$35.00$11.27210.56%102.08%
Jan 21, 2026Brad CaninoGuggenheim$35.00$13.98150.36%102.08%
Dec 04, 2025Stephen WilleyStifel Nicolaus$32.00$12.99146.34%84.76%
Aug 25, 2025Jefferies$26.00$14.7076.87%50.12%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 16, 2026H.C. WainwrightNeutralNeutralhold
Jun 01, 2026H.C. WainwrightNeutralNeutraldowngrade
Jan 28, 2026Piper SandlerOverweightinitialise
Jan 21, 2026GuggenheimBuyinitialise
Aug 25, 2025JefferiesBuyinitialise
Jul 14, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-15K $-12K $-9K $-6K $-3K $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-1.23$-0.89$-0.58$-0.59$-12.82K--
Avg Forecast$-2.65$-0.98$-0.16$-0.03$-7.88$-4.94$-2.99
High Forecast$-2.65$-0.98$-0.16$-0.03$-6.00$-3.31$-1.98
Low Forecast$-2.65$-0.98$-0.16$-0.03$-10.47$-8.00$-3.58
Surprise %-53.58%-9.18%262.50%1866.67%162565.10%--

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.16M$75.00K$10.00K----
Avg Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
High Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Low Forecast$757.91K$794.00K$1.59M$105.76M$65.00M$39.95M$5.63M
Surprise %53.02%-90.55%-99.37%----

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-63.43M$-46.69M$-36.90M$-71.47M$-149.94M--
Avg Forecast$-83.60M$-30.91M$-5.93M$-30.69K$-8.42M$-5.78M$-2.84M
High Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-6.14M$-3.39M$-2.03M
Low Forecast$-83.60M$-30.91M$-5.05M$-30.69K$-10.71M$-8.18M$-3.66M
Surprise %-24.13%51.02%522.46%232785.82%1679.96%--

CBIO Forecast FAQ

Is Crescent Biopharma stock a buy?

Crescent Biopharma stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Crescent Biopharma is a favorable investment for most analysts.

What is Crescent Biopharma's price target?

Crescent Biopharma's price target, set by 13 Wall Street analysts, averages $29 over the next 12 months. The price target range spans from $29 at the low end to $29 at the high end, suggesting a potential 67.44% change from the previous closing price of $17.32.

How does Crescent Biopharma stock forecast compare to its benchmarks?

Crescent Biopharma's stock forecast shows a 67.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Crescent Biopharma over the past three months?

  • August 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Crescent Biopharma’s EPS forecast?

Crescent Biopharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.94, marking a -99.96% decrease from the reported $-12.818K in 2025. Estimates for the following years are.

What is Crescent Biopharma’s revenue forecast?

Crescent Biopharma's average annual revenue forecast for its fiscal year ending in December 2026 is $39.95M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Crescent Biopharma’s net income forecast?

Crescent Biopharma's net income forecast for the fiscal year ending in December 2026 stands at $-5.785M, representing a -96.14% decrease from the reported $-150M in 2025. Projections indicate .